Physician profile
Sheri Ann Loo
NPI 1932627221
$2,067.67
in general payments reported to CMS, 2019-2025
17 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.13 · 2022: $453 · 2023: $854 · 2024: $368 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,565.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $242.41 | 2022-2023 | Evenity |
| Edwards Lifesciences Corporation | $167.86 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Averitas Pharma INC. | $130.00 | 2023 | Qutenza |
| Vertos Medical, INC. | $128.23 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.57 | 2023 | |
| Gilead Sciences, INC. | $124.44 | 2023 | Epclusa |
| Mayne Pharma Commercial LLC | $123.83 | 2023 | |
| Nuvasive, INC. | $122.15 | 2023 | Attrax |
| Biogen, INC. | $121.85 | 2024 | Spinraza |
| Argenx US, INC. | $121.82 | 2025 | Vyvgart |
| Amarin Pharma, INC. | $117.78 | 2025 | Vascepa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $111.48 | 2022 | |
| Abbvie INC. | $110.76 | 2023 | |
| Corcept Therapeutics | $103.40 | 2025 | Korlym |
| Scynexis, INC. | $88.49 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $78.47 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $49.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheri Loo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.